Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Does 177Lu-labeled octreotate improve the rate of remission of endocrine gastroenteropancreatic tumors?

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. Otte A et al. (1997) DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24: 792–795

    CAS  PubMed  Google Scholar 

  2. Eberle AN et al. (2004) Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors. J Recept Signal Transduct 24: 319–455

    Article  CAS  Google Scholar 

  3. Jamar F et al. (2003) 86Y-DOTA-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30: 510–518

    Article  CAS  Google Scholar 

  4. Paganelli G et al. (2002) 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 66: 393–398

    Article  CAS  Google Scholar 

  5. De Jong et al. (2005) Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 46 (Suppl 1): 13S–17S

    Google Scholar 

Download references


The synopsis was written by Ian Newman, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Alex N Eberle.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Eberle, A., Beglinger, C. Does 177Lu-labeled octreotate improve the rate of remission of endocrine gastroenteropancreatic tumors?. Nat Rev Endocrinol 1, 20–21 (2005).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing